Back to News
Activism

Activist Investing Today: What's Next at Third Point-Targeted Sony

|
Published: January 22nd, 2021
Our own Chris Nolter spoke to Activist Investing Today about prospects for an acquisition of Sony's entertainment assets now that Third Point's Dan Loeb seems out to shake things up at the Japanese multinational.

The Deal’s senior telecom, media and technology writer Chris Nolter talked to Activist Investing Today about prospects for acquiring Sony’s entertainment assets now that Third Point’s Dan Loeb seems out to shake things up at the Japanese multinational.

Nolter noted that Sony owns a major Hollywood studio and that “there just are not that many of them, so it has always been valuable.” Nolter points to a bidding war that led to a sweetened $71 billion sale of Fox’s TV production and other operations to Disney as indicative of potential buyer interest in Sony’s entertainment assets. He explained that Sony could set up a joint venture of sorts as an alternative to a sale. The podcast also weighed other aspects of a potential Third Point campaign, such as a change in management, a governance stewardship code and new Japanese tax laws for spinoffs.

Here’s the podcast:

More podcasts from The Deal are available on iTunes, Spotify, and on TheDeal.com.

More From Activism

Activism

Activist Investing Today: Eldar on Anti-Activist Pill Evolution

By Ronald Orol
|
Published: May 23rd, 2025
When corporations install anti-activist poison pills they're less likely to implement new share buybacks and their operationally focused capital expenditures tend to be higher, UC Berkeley School of Law professor Ofer Eldar explains.
Activism

Pills Emerge Amid Tariff Uncertainty, Activism

By Ronald Orol
|
Published: April 28th, 2025
As the markets face tariff-related volatility, some companies, especially biotechnology and pharmaceuticals companies, are setting up or extending shareholder rights plans, known as poison pills, to discourage unsolicited bidders and activist accumulations.